By Sam Boughedda
Investing.com — Biotechnology company Nanobiotix (NASDAQ:) shares rallied 23% on Thursday after it revealed after Wednesday’s closing bell that it has enrolled the first patient in a phase 3 study of its treatment for head and neck cancer.
The study is designed to investigate the efficacy and safety of radiotherapy-activated NBTXR3 in high-risk, chemotherapy-ineligible elderly patients with locally advanced head and neck cancer. The trial follows on from the Nanobiotix Study 102, a phase 1 trial evaluating safety and early signs of efficacy.
The U.S. Food and Drug Administration has granted Fast Track designation to investigate radiotherapy-activated NBTXR3, giving it the opportunity for priority review and accelerated approval.
“The first patient enrolled in our global phase III study is a testament to the tireless commitment of our team, investigators, and strategic collaborators,” said Laurent Levy, co-founder and chairman of the executive board at Nanobiotix.
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.